Maybe I give managment to much credit but I think they just slipped this information in here ( with interim financial statements) to inform their shareholders where we are in the overall plan for POET and rather not attract any more attention from anyone else.

"With an immediate view to commercialization, the Company has continued to develop the base process technology necessary to build the complete suite of optoelectronicsand devices.

The new management team is focused on exploiting existing high growth markets where the disruptive power of the POET platform IP provides competitive differentiation."

The core source of technology differentiation has been validated in the laboratory at the University of Connecticut, and with that the Company is positioning itself to take its technology to the commercialization phase.

The Company has, for the first time, engaged commercial epitaxial wafer suppliers in providing wafers with the unique and proprietary POET epitaxial stack.

While comprehensive discussions are underway with a number of potential foundry and epitaxial wafer partners, we have recently signed memorandums of understanding with some of these companies and expect to continue this process.

This should accelerate the lab-fab transition, utilizing state of the art processes that position the Company for success in defined commercial markets.

"We are pleased to be working with well-established companies as both our foundry partners and as suppliers of our proprietary epitaxial wafers," said Dr. Venkatesan.

"We are focused on monetizing the technology in existing and proven high growth markets where the disruptive technology innovations will provide a relevant and sustained source of competitive differentiation.

We will be communicating the vision, objectives and accelerated drive to product realization around the end of September."